ARCT
Price
$22.17
Change
+$1.86 (+9.16%)
Updated
Sep 26 closing price
Capitalization
602.02M
38 days until earnings call
MRNA
Price
$24.49
Change
-$0.12 (-0.49%)
Updated
Sep 26 closing price
Capitalization
9.53B
32 days until earnings call
Interact to see
Advertisement

ARCT vs MRNA

Header iconARCT vs MRNA Comparison
Open Charts ARCT vs MRNABanner chart's image
Arcturus Therapeutics Holdings
Price$22.17
Change+$1.86 (+9.16%)
Volume$915.68K
Capitalization602.02M
Moderna
Price$24.49
Change-$0.12 (-0.49%)
Volume$10.24M
Capitalization9.53B
ARCT vs MRNA Comparison Chart in %
Loading...
ARCT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MRNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ARCT vs. MRNA commentary
Sep 29, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARCT is a StrongBuy and MRNA is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 29, 2025
Stock price -- (ARCT: $22.17 vs. MRNA: $24.49)
Brand notoriety: ARCT: Not notable vs. MRNA: Notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARCT: 144% vs. MRNA: 96%
Market capitalization -- ARCT: $602.02M vs. MRNA: $9.53B
ARCT [@Biotechnology] is valued at $602.02M. MRNA’s [@Biotechnology] market capitalization is $9.53B. The market cap for tickers in the [@Biotechnology] industry ranges from $98.9B to $0. The average market capitalization across the [@Biotechnology] industry is $1.89B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARCT’s FA Score shows that 0 FA rating(s) are green whileMRNA’s FA Score has 1 green FA rating(s).

  • ARCT’s FA Score: 0 green, 5 red.
  • MRNA’s FA Score: 1 green, 4 red.
According to our system of comparison, ARCT is a better buy in the long-term than MRNA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARCT’s TA Score shows that 4 TA indicator(s) are bullish while MRNA’s TA Score has 3 bullish TA indicator(s).

  • ARCT’s TA Score: 4 bullish, 4 bearish.
  • MRNA’s TA Score: 3 bullish, 4 bearish.
According to our system of comparison, ARCT is a better buy in the short-term than MRNA.

Price Growth

ARCT (@Biotechnology) experienced а +8.36% price change this week, while MRNA (@Biotechnology) price change was -2.97% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.00%. For the same industry, the average monthly price growth was +9.18%, and the average quarterly price growth was +54.60%.

Reported Earning Dates

ARCT is expected to report earnings on Nov 05, 2025.

MRNA is expected to report earnings on Oct 30, 2025.

Industries' Descriptions

@Biotechnology (+4.00% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MRNA($9.53B) has a higher market cap than ARCT($602M). ARCT YTD gains are higher at: 30.642 vs. MRNA (-41.101). ARCT has higher annual earnings (EBITDA): -54.54M vs. MRNA (-2.72B). MRNA has more cash in the bank: 5.13B vs. ARCT (196M). ARCT has less debt than MRNA: ARCT (27M) vs MRNA (741M). MRNA has higher revenues than ARCT: MRNA (3.06B) vs ARCT (110M).
ARCTMRNAARCT / MRNA
Capitalization602M9.53B6%
EBITDA-54.54M-2.72B2%
Gain YTD30.642-41.101-75%
P/E RatioN/AN/A-
Revenue110M3.06B4%
Total Cash196M5.13B4%
Total Debt27M741M4%
FUNDAMENTALS RATINGS
ARCT vs MRNA: Fundamental Ratings
ARCT
MRNA
OUTLOOK RATING
1..100
3113
VALUATION
overvalued / fair valued / undervalued
1..100
46
Fair valued
55
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9697
PRICE GROWTH RATING
1..100
3765
P/E GROWTH RATING
1..100
1003
SEASONALITY SCORE
1..100
5085

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ARCT's Valuation (46) in the Pharmaceuticals Major industry is in the same range as MRNA (55) in the Biotechnology industry. This means that ARCT’s stock grew similarly to MRNA’s over the last 12 months.

ARCT's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as MRNA (100) in the Biotechnology industry. This means that ARCT’s stock grew similarly to MRNA’s over the last 12 months.

ARCT's SMR Rating (96) in the Pharmaceuticals Major industry is in the same range as MRNA (97) in the Biotechnology industry. This means that ARCT’s stock grew similarly to MRNA’s over the last 12 months.

ARCT's Price Growth Rating (37) in the Pharmaceuticals Major industry is in the same range as MRNA (65) in the Biotechnology industry. This means that ARCT’s stock grew similarly to MRNA’s over the last 12 months.

MRNA's P/E Growth Rating (3) in the Biotechnology industry is significantly better than the same rating for ARCT (100) in the Pharmaceuticals Major industry. This means that MRNA’s stock grew significantly faster than ARCT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARCTMRNA
RSI
ODDS (%)
Bearish Trend 3 days ago
90%
N/A
Stochastic
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
87%
Momentum
ODDS (%)
Bullish Trend 3 days ago
79%
Bullish Trend 3 days ago
74%
MACD
ODDS (%)
Bullish Trend 3 days ago
90%
Bullish Trend 3 days ago
83%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
83%
Bearish Trend 3 days ago
86%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
80%
Bearish Trend 3 days ago
85%
Advances
ODDS (%)
Bullish Trend 7 days ago
80%
Bullish Trend 11 days ago
77%
Declines
ODDS (%)
Bearish Trend 12 days ago
87%
Bearish Trend 3 days ago
85%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
80%
Aroon
ODDS (%)
N/A
Bearish Trend 3 days ago
85%
View a ticker or compare two or three
Interact to see
Advertisement
ARCT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MRNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
BJUL49.430.19
+0.40%
Innovator U.S. Equity Buffer ETF July
BKCG35.360.14
+0.40%
BNY Mellon Concentrated Growth ETF
INKM33.020.12
+0.35%
SPDR® SSgA Income Allocation ETF
ZTAX24.66N/A
N/A
X-Square Municipal Income Tax Free ETF
TLTW23.26-0.01
-0.04%
iShares 20+ Year Trs Bd Buywrt Stgy ETF

ARCT and

Correlation & Price change

A.I.dvisor indicates that over the last year, ARCT has been loosely correlated with CLDX. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if ARCT jumps, then CLDX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARCT
1D Price
Change %
ARCT100%
+9.16%
CLDX - ARCT
52%
Loosely correlated
+3.52%
RGNX - ARCT
49%
Loosely correlated
+3.10%
OVID - ARCT
46%
Loosely correlated
+22.70%
MRNA - ARCT
46%
Loosely correlated
-0.49%
MGNX - ARCT
45%
Loosely correlated
+4.85%
More

MRNA and

Correlation & Price change

A.I.dvisor indicates that over the last year, MRNA has been loosely correlated with BNTX. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if MRNA jumps, then BNTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MRNA
1D Price
Change %
MRNA100%
-0.49%
BNTX - MRNA
54%
Loosely correlated
N/A
NVAX - MRNA
51%
Loosely correlated
+2.52%
TECH - MRNA
47%
Loosely correlated
+2.71%
ARCT - MRNA
46%
Loosely correlated
+9.16%
CRSP - MRNA
45%
Loosely correlated
+2.24%
More